UNSPSC 51152055: Dotefonium bromide

This classification denotes a muscle relaxant with the molecular formula C20H27N2O2S.Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D762286A5N, chemically known as pyrrolidinium, 1-methyl-1-(2-(n-methyl-alpha-2-thienylmandelamido)ethyl)-, bromide but more generally known as dotefonium bromide, which bears US NIH Compound Identifier 71913. European Medicines Agency schedules Dotefonium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06379MIG.

UNSPSC 51152055 Dotefonium bromide, a Commodity code, nominally addresses a single pharmaceutical product, but recent state and local opportunities tagged under it reflect broader pharmaceutical procurement activity — specifically naloxone and drug deactivation systems for community health programs, and exploratory contracting for direct-to-manufacturer prescription fulfillment models. The code appears to serve as a catch-all for pharmaceutical-related procurements that do not map cleanly to narrower commodity definitions. Issuing bodies include county health departments and state health and human services commissions pursuing either direct supply contracts for regulated pharmaceuticals or exploratory market intelligence on alternative pharmacy distribution models. The work involves fulfilling community health initiatives, managing drug-disposal compliance, and in some cases restructuring state-level pharmacy benefit arrangements to bypass traditional pharmacy benefit manager intermediaries.

Recent activity spans Florida and Texas. Seminole County, Florida issued an IFB in June 2026 (IFB60459723LAS, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries and fixed-fee pricing on a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission posted an RFI in April 2026 (HHS0017013, closed April 3, 2026) to gather vendor capabilities on implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling exploratory procurement at the state level before a formal RFP. Neither opportunity specifies explicit set-aside designations. The Seminole County work is concrete and near-term; the Texas activity is preliminary market research that will likely precede a larger formal solicitation, but the breadth of the RFI suggests significant procurement intent once specifications solidify.